What Is Ectris (Flibanserin, Girosa)?
Ectris (Flibanserin, Girosa) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
Ectris (Flibanserin) works in the central nervous system, which regulates sexual desire.
Ectris (Flibanserin) acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.
Clinical studies are underway to better understand this investigational compound and how it may impact women with Hypoactive Sexual Desire Disorder (HSDD).
Ectris (flibanserin) Phase III Study Results
Ectris (Flibanserin) Phase III trials study presented at the Congress of the European Society for Sexual Medicine in Lyon, shows positive results with pre-menopausal women taking Ectris (flibanserin 100mg) once-daily at bedtime, increasing the number of Satisfying Sexual Events (SSEs) and decreasing significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
Phase III Clinical Trial Results in North America
Analysis of 1,378 pre-menopausal women taking Ectris (Flibanserin 100mg) during 24-week study period, shows significant increase in the frequency of Satisfying Sexual Events (SSEs) per month from 2.8 at baseline to 4.5 versus placebo 2.7 at baseline increasing to 3.7.
Other key secondary endpoints showed Ectris (flibanserin) significantly improved sexual functioning as measured by data from the desire domain of the Female Sexual Function Index (FSFI).
Recently Boehringer Ingelheim presented new data from Phase III clinical trials of Ectris (Flibanserin 100 mg) at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco.
Ectris
(Flibanserin 100 mg)
New Phase III Data in USA reported positive results
Safety Analysis
Ectris (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common adverse drug reactions reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.
Boehringer Ingelheim was conducting Phase III clinical trials evaluating Ectris (Flibanserin) in over 2,000 women at 360 locations in the USA, Canada and Europe.
Flibanserin’s effects are believed to improve a woman’s decreased sexual desire gradually over time and a Phase III study results programme show that Ectris (flibanserin 100mg) is well-tolerated and effective in pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).
USA Flibanserin 100 mg active clinical trials
Women 18 to 55 years of age diagnosed with Hypoactive Sexual Desire Disorder with a monogamous heterosexual relationship for at least one year, can now participate in clinical trials across the USA and Canada to test the safety and efficacy of flibanserin 100 mg in naturally postmenopausal women.
For further information visit the following link:
http://clinicaltrials.gov/ct2/results?term=flibanserin&recr=Open&s
Ectris (Flibanserin, Girosa ) Side Effects
Phase III Clinical Trials ResultsGirosa (flibanserin 100mg) adverse events were mild to moderate, emerged during the first 14 days of treatment and resolved with continued treatment.
The most common side effects reported by more women on Ectris (flibanserin) than on placebo included dizziness, nausea, fatigue, somnolence and insomnia.
Can I buy Ectris Girosa (flibanserin, Girosa )?
No, Ectris (Flibanserin) is not yet available for sale.
Wednesday, May 26, 2010
Ectris / Girosa (flibanserin) libido pills for women
Ectris / Girosa (flibanserin) libido pills for women
Ectris (Flibanserin) is an non-hormonal compound being studied as a potential oral daily treatment for pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).
Ectris (Flibanserin) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
"It's essentially a drug that raises dopamine, the chemical that increases interest," said Irwin Goldstein of Alvarado Hospital's Sexual Medicine Center in San Diego.
Ectris / Girosa (Flibanserin) works on the central nervous system and acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.
Recent Phase III clinical trials results presented at the Congress of the European Society for Sexual Medicine in Lyon, demonstrated that Girosa (flibanserin 100mg) taken once-daily at bedtime, increase the number of Satisfying Sexual Events (SSEs) and decrease significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
Ectris (Flibanserin) is an non-hormonal compound being studied as a potential oral daily treatment for pre-menopausal women suffering Hypoactive Sexual Desire Disorder (HSDD).
Ectris (Flibanserin) could be the first oral product for the treatment of HSDD (hypoactive sexual desire disorder in menopausal women) in the U.S.
"It's essentially a drug that raises dopamine, the chemical that increases interest," said Irwin Goldstein of Alvarado Hospital's Sexual Medicine Center in San Diego.
Ectris / Girosa (Flibanserin) works on the central nervous system and acts as a 5-HT1A serotonin receptor agonist and 5-HT2A serotonin receptor antagonist.
Recent Phase III clinical trials results presented at the Congress of the European Society for Sexual Medicine in Lyon, demonstrated that Girosa (flibanserin 100mg) taken once-daily at bedtime, increase the number of Satisfying Sexual Events (SSEs) and decrease significantly the distress associated with Hypoactive Sexual Desire Disorder (HSDD).
Monday, May 24, 2010
‘Viagra’ for women to hit the shelves soon
Good news for women who want to perk up the action in their bedroom-the Food and Drug Administration committee is thinking of endorsing the first pill designed to do for women what Viagra does for men-boost their sex lives.
A German pharmaceutical giant wants to sell a drug with the decidedly unsexy name “flibanserin,” which has shown prowess for sparking a woman’s sexual desire by fiddling with her brain chemicals.
The FDA’s Reproductive Health Drugs Advisory Committee will meet on June 18 to consider the request.
But the prospect of the drug’s approval has already triggered debate over whether the medication, like others in the pipeline, represents a long-sought step toward equity for women’s health or the latest example of the pharmaceutical industry fabricating a questionable disorder to sell unnecessary and potentially dangerous drugs.
“Achieving a happy and healthy sex life can be a real and important problem for some women. But we have lots of questions about the ‘pink Viagra,’” the Washington Post quoted Amy Allina of the National Women’s Health Network, a Washington-based advocacy group, as saying.
Viagra’s catapult to blockbuster status after its 1998 approval set off a flurry of interest in me-too medications for women.
However, drugmaker Pfizer’s hopes that its “little blue pill” would also ignite female libido fizzled, making it clear that a woman’s sexuality is more complicated than a man’s.
But, Germany’s Boehringer Ingelheim is optimistic that flibanserin is on the verge of becoming the first prescription medication to tap what some have estimated could be a 2 billion dollar market in the United States alone.
“We believe women deserve options and we’re hoping flibanserin may represent a safe and effective option for many women,” said Michael Sand, who heads the company’s clinical research on flibanserin.
Scientists found that flibanserin, developed as an antidepressant, was ineffective for treatment of depression.
But the drug appeared to produce an unexpected side effect: boosting women’s libido.
This prompted the company to study it for hypoactive sexual desire disorder, or HSDD, an otherwise unexplained loss of sexual thoughts, fantasies and desire that can cause significant emotional distress.
Some research suggests 10 percent of women may suffer from HSDD.
“It’s not that they are averse to sex. It’s just that they don’t care about it. They just stop thinking about it. It’s like a switch has been flipped. It’s a loss for them. They miss it. And they want it back,” said Anita H. Clayton, a professor of psychiatry and neurobehavioral sciences at the University of Virginia who has studied the drug for the company. (ANI)
A German pharmaceutical giant wants to sell a drug with the decidedly unsexy name “flibanserin,” which has shown prowess for sparking a woman’s sexual desire by fiddling with her brain chemicals.
The FDA’s Reproductive Health Drugs Advisory Committee will meet on June 18 to consider the request.
But the prospect of the drug’s approval has already triggered debate over whether the medication, like others in the pipeline, represents a long-sought step toward equity for women’s health or the latest example of the pharmaceutical industry fabricating a questionable disorder to sell unnecessary and potentially dangerous drugs.
“Achieving a happy and healthy sex life can be a real and important problem for some women. But we have lots of questions about the ‘pink Viagra,’” the Washington Post quoted Amy Allina of the National Women’s Health Network, a Washington-based advocacy group, as saying.
Viagra’s catapult to blockbuster status after its 1998 approval set off a flurry of interest in me-too medications for women.
However, drugmaker Pfizer’s hopes that its “little blue pill” would also ignite female libido fizzled, making it clear that a woman’s sexuality is more complicated than a man’s.
But, Germany’s Boehringer Ingelheim is optimistic that flibanserin is on the verge of becoming the first prescription medication to tap what some have estimated could be a 2 billion dollar market in the United States alone.
“We believe women deserve options and we’re hoping flibanserin may represent a safe and effective option for many women,” said Michael Sand, who heads the company’s clinical research on flibanserin.
Scientists found that flibanserin, developed as an antidepressant, was ineffective for treatment of depression.
But the drug appeared to produce an unexpected side effect: boosting women’s libido.
This prompted the company to study it for hypoactive sexual desire disorder, or HSDD, an otherwise unexplained loss of sexual thoughts, fantasies and desire that can cause significant emotional distress.
Some research suggests 10 percent of women may suffer from HSDD.
“It’s not that they are averse to sex. It’s just that they don’t care about it. They just stop thinking about it. It’s like a switch has been flipped. It’s a loss for them. They miss it. And they want it back,” said Anita H. Clayton, a professor of psychiatry and neurobehavioral sciences at the University of Virginia who has studied the drug for the company. (ANI)
Subscribe to:
Posts (Atom)
